December 17, 2025
theresa-g-avatar-small - light bg
Morning Rounds Writer and Reporter

Good morning. Lots of news today, including more details from Sarah Todd on what she calls the "peculiar politics" around the act passed by the House this week to bring whole milk back to schools. 

Hhs

As the year ends, RFK Jr. presses on

Andrew Harnik/Getty Images

When Robert F. Kennedy Jr. took over as health secretary, he launched a sweeping overhaul of his department — reducing its workforce by 20% and refocusing it on his Make America Healthy Again agenda. Months later, there have been some clear hurdles: Some of the firings are tied up in legal battles, and the creation of his chronic disease-focused agency stalled in Congress. 

But as STAT’s Chelsea Cirruzzo reports, Kennedy soldiers on, using his reorganization to cement his power. “The current secretary is incredibly insular, and he’s not relying on his legislative affairs team in policy conversations,” said Melanie Egorin, former HHS assistant secretary for legislation under the Biden administration.

Read more on Kennedy’s purported “MAHA wins,” the state of play at HHS, and which lawmakers might serve as a check on Kennedy in 2026.


policy

Two rare diseases added to newborn screening recs

Yesterday, Kennedy announced that two deadly rare diseases — Duchenne muscular dystrophy and metachromatic leukodystrophy (MLD) — were added to the list of conditions the government recommends states screen newborns for. 

The news came eight months after HHS under Kennedy disbanded the expert committee that reviews new diseases, upending years-long efforts to get both conditions added to the list. Still, advocates greeted the move as a critical step toward enabling earlier diagnosis and treatment. Read more from STAT’s Jason Mast on what it means and what we know about how the process ultimately played out.


first opinion

A new antibiotic isn’t just good for science — it’s good for business

After decades of reliance on the same, increasingly ineffective treatments for gonorrhea, two new first-in-class antibiotics were approved by the FDA within a day of each other last week. Both drugs offer urgently needed options for the common STI, as they both work through novel mechanisms that are active against drug-resistant strains.

Today, we have a First Opinion essay from the leader of one of the organizations that made this accomplishment possible. Manica Balasegaram, the executive director of the Global Antibiotic Research & Development Partnership (GARDP), writes that even more remarkable than the science is how one of the drugs was developed, through a new kind of not-for-profit research and development model.

“It’s a radical approach — and one in which everyone wins,” Balasegaram writes. Read more in her essay on how GARDP is working to make the new drug accessible outside the U.S. as soon as possible. 



brain drain

After this year, some scientists are saying goodbye to the U.S.

Naïma Lecomte for STAT 

Pleuni Pennings (above) was already in Europe — on a sabbatical of sorts in the south of France — watching from afar as the second Trump administration started tearing into the scientific research system earlier this year. She and her family weren’t planning to stay, but between her pessimism about receiving grant funding and her anxiety about the immigration crackdown given her own status as a green card holder, they did.

Pennings is an embodiment of the “brain drain” concern that many experts have raised as the Trump administration’s upheaval of science continues. While experts who track the scientific labor force say it’s too soon to know how many scientists have left the U.S., it’s clear that at least some movement is occurring. STAT’s Andrew Joseph spoke with a half-dozen scientists who have left or are in the process of leaving the U.S. Read more to learn about the two big reasons people are planning to jump ship. It’s the latest in our American Science, Shattered series. Catch up on the previous stories here. And there’s more to come this week.


cardio

Stress heightens risk of cardiovascular disease in people with anxiety and depression

Anxiety or depression aren’t good for heart health, a large new study says. Together, they drive the risk for heart attack, heart failure, or stroke even higher. But how? Researchers have found clues in the body’s “fight or flight” reactions, the stress response that sends the heart racing, revs up blood pressure, and triggers chronic inflammation. When it’s overactive, this stress-related activity, tracked by neuroimaging in the brain and biomarkers of inflammation in the blood, damages blood vessels and accelerates heart disease.

Data from participants in the Mass General Brigham Biobank who had anxiety, depression, or both were followed for almost three and a half years. People with both anxiety and depression had a 32% higher risk of cardiovascular disease over that time compared to people with just anxiety or depression, a level that held true after accounting for factors like socioeconomic status, smoking, diabetes, and hypertension.

The observational study can’t show cause and effect, so the authors of the study, published today in Circulation: Cardiovascular Imaging, say more research is needed to nail down any direct role of depression and/or anxiety. The authors will also study possible treatments to see if stress-reduction therapies, anti-inflammatory medications, or lifestyle changes might lower risk for serious cardiovascular events.

“Together, these changes seem to form a biological chain linking emotional stress to cardiovascular risk,” study co-author Abohashem said in a statement. “This reinforces that protecting heart health isn’t just about diet or exercise, it’s also about emotional health.” — Elizabeth Cooney


one big number

$2.63 million

That’s how much science whistleblower Sholto David will receive as part of a $15 million settlement over misrepresented data and images in research by scientists from the Dana-Farber Cancer Institute. Drew visited David at his home in Pontypridd, Wales, in January 2024, less than a month after David published a blog post outlining the errors that he and other sleuths had noticed. “I’m not a successful researcher, am I? Let’s be realistic,” David told Drew. “But I’m seeing all these people who’ve got these high-flying careers and they’re just bloody Photoshopping all the blots. Wouldn’t you be mad about that?”

Revisit that story, then read Jonathan Wosen’s report on David’s big pay day. 


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • New head of Trump's cancer panel speculated about links between vaccines and cancer, Wired

  • CDC approves new hepatitis B vaccine recommendation as some hospitals reject changes, STAT
  • Heart association revives theory that light drinking may be good for you, New York Times
  • Former NIH leader Jeanne Marrazzo sues administration over termination,